Ocumension Therapeutics
HKEX:1477

Watchlist Manager
Ocumension Therapeutics Logo
Ocumension Therapeutics
HKEX:1477
Watchlist
Price: 4.41 HKD 0.46% Market Closed
Market Cap: 3.6B HKD
Have any thoughts about
Ocumension Therapeutics?
Write Note

Ocumension Therapeutics
Accrued Liabilities

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Ocumension Therapeutics
Accrued Liabilities Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Accrued Liabilities CAGR 3Y CAGR 5Y CAGR 10Y
Ocumension Therapeutics
HKEX:1477
Accrued Liabilities
ÂĄ25.3m
CAGR 3-Years
45%
CAGR 5-Years
85%
CAGR 10-Years
N/A
H
Hansoh Pharmaceutical Group Company Ltd
HKEX:3692
Accrued Liabilities
ÂĄ2B
CAGR 3-Years
2%
CAGR 5-Years
14%
CAGR 10-Years
N/A
Zhangzhou Pientzehuang Pharmaceutical Co Ltd
SSE:600436
Accrued Liabilities
ÂĄ620.1m
CAGR 3-Years
74%
CAGR 5-Years
53%
CAGR 10-Years
31%
Jiangsu Hengrui Pharmaceuticals Co Ltd
SSE:600276
Accrued Liabilities
ÂĄ128.5m
CAGR 3-Years
456%
CAGR 5-Years
130%
CAGR 10-Years
63%
Yunnan Baiyao Group Co Ltd
SZSE:000538
Accrued Liabilities
ÂĄ1.5B
CAGR 3-Years
74%
CAGR 5-Years
54%
CAGR 10-Years
46%
S
Sichuan Biokin Pharmaceutical Co Ltd
SSE:688506
Accrued Liabilities
ÂĄ146m
CAGR 3-Years
-11%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

Ocumension Therapeutics
Glance View

Market Cap
3.6B HKD
Industry
Pharmaceuticals

Ocumension Therapeutics engages in the identification, development, and commercialization of ophthalmic therapies. The company is headquartered in Suzhou, Jiangsu. The company went IPO on 2020-07-10. Its main products include OT-401 (YUTIQ), OT-1001 (ZERVIATE), OT-502 (DEXYCU), OT-301 (NCX 470), OT-101 and OT-202, among others. The firm conducts its businesses in the domestic market.

Intrinsic Value
5.8 HKD
Undervaluation 24%
Intrinsic Value
Price

See Also

What is Ocumension Therapeutics's Accrued Liabilities?
Accrued Liabilities
25.3m CNY

Based on the financial report for Dec 31, 2023, Ocumension Therapeutics's Accrued Liabilities amounts to 25.3m CNY.

What is Ocumension Therapeutics's Accrued Liabilities growth rate?
Accrued Liabilities CAGR 5Y
85%

Over the last year, the Accrued Liabilities growth was 67%. The average annual Accrued Liabilities growth rates for Ocumension Therapeutics have been 45% over the past three years , 85% over the past five years .

Back to Top